| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 23029 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated |
| Assessment Process | |
| Rapid review commissioned | 31/05/2023 |
| Rapid review completed | 13/06/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with abiraterone and prednisone or prednisolone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/06/2023 |
